Our knowledge of the structure of voltage-dependent K + (Kv) channels, which shape the neuronal action potential, has come largely from studies of prokaryotic channels, which can be expressed at ...

Our current work revolves around two main topics: targeting potassium channels for the treatment of chronic diseases (multiple sclerosis, rheumatoid arthritis, and type 1 myotonic dystrophy) and using ...

Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in FOS and findings around ...

Icagen Inc. has disclosed potassium voltage-gated channel subfamily KQT member 2 (KCNQ2; Kv7.2) activators reported to be useful for the treatment of pain, Alzheimer’s disease, epilepsy, motor neuron ...

We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel ...